PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, marking a major milestone in its growth journey. With this funding, PlasmaGen has now raised over ₹600 crore to date, backed by prominent investors such as Eight Roads, FIL Capital, and F-Prime.
The funding round is a testament to the company’s strong potential and its commitment to delivering high-quality plasma-derived products. PlasmaGen operates one of India’s five plasma fractionation facilities near Bengaluru, which is a critical infrastructure for the production of life-saving therapies. The company’s state-of-the-art facility is equipped with cutting-edge technology and adheres to international standards, ensuring the production of high-quality plasma-derived products.
The Indian biotechnology sector has been witnessing significant growth in recent years, driven by government initiatives, increasing demand for healthcare services, and a growing pool of talented professionals. The sector has attracted significant investments from both domestic and international investors, with many startups and established companies raising funds to scale up their operations.
PlasmaGen’s funding round is a notable example of this trend, with the company raising ₹150 crore in a single round. The investment will be used to further expand the company’s operations, enhance its product portfolio, and strengthen its research and development capabilities. With a strong focus on innovation and quality, PlasmaGen is well-positioned to capitalize on the growing demand for plasma-derived products in India and globally.
The company’s plasma fractionation facility is a critical component of its operations, enabling the production of a range of life-saving therapies. Plasma fractionation is a complex process that involves the separation of plasma into various components, which are then used to produce therapies for various diseases and disorders. The facility is equipped with advanced technology and equipment, ensuring the production of high-quality products that meet international standards.
PlasmaGen’s commitment to quality and innovation has earned it a reputation as a leading player in the Indian biotechnology sector. The company’s products are used to treat a range of diseases and disorders, including hemophilia, immunodeficiency disorders, and neurological disorders. With a strong focus on research and development, PlasmaGen is continuously working to expand its product portfolio and develop new therapies that address unmet medical needs.
The funding round led by ViNS Bioproducts is a significant endorsement of PlasmaGen’s growth potential and its commitment to delivering high-quality products. ViNS Bioproducts is a leading player in the biotechnology sector, with a strong focus on investing in companies that have the potential to make a significant impact in the industry. The investment in PlasmaGen is a testament to the company’s strong fundamentals and its potential for long-term growth.
In addition to ViNS Bioproducts, PlasmaGen is backed by other prominent investors, including Eight Roads, FIL Capital, and F-Prime. These investors have a strong track record of investing in successful biotechnology companies and have provided significant support to PlasmaGen in its growth journey.
The Indian biotechnology sector is expected to continue growing in the coming years, driven by government initiatives, increasing demand for healthcare services, and a growing pool of talented professionals. With a strong focus on innovation, quality, and research and development, PlasmaGen is well-positioned to capitalize on this growth and emerge as a leading player in the industry.
In conclusion, PlasmaGen’s funding round is a significant development in the Indian biotechnology sector, marking a major milestone in the company’s growth journey. With a strong focus on quality, innovation, and research and development, PlasmaGen is committed to delivering high-quality plasma-derived products that address unmet medical needs. The company’s valuation crossing ₹1,500 crore is a testament to its strong potential and its commitment to making a significant impact in the industry.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
